News and Press Releases
Exploristics and Exonate announce successful collaboration to enhance clinical trial study design using cloud-based simulation
Exploristics’ cloud-based simulation platform KerusCloud used to enhance study design for Exonate’s upcoming phase 2b study following successful phase 1b/2a study 12 March 2024 -- Cambridgeshire and Belfast, UK --...
Category: Clinical Trials
Posted: March 12, 2024
EmpowerPharm Awaits Phase 2 Clinical Trial on Ground-Breaking Treatment to Manage Social Anxiety Disorder
First Cannabidiol treatment study of its kind to be approved by the FDA 11 March 2024 -- Ontario, Canada -- EmpowerPharm is delighted to announce that the final participant has completed...
Category: Clinical Trials, Pharmaceutical
Posted: March 11, 2024
Education and tailored communications are required to bridge the ethnicity gap in clinical trial participation
6 in 10 (58%) adults in the UK reported that they would be willing to participate in a clinical trial. However, ethnic minority adults were significantly less likely to participate,...
Category: Clinical Trials
Posted: March 11, 2024
ICR scientists seek new drugs to treat childhood cancer as part of global Cancer Grand Challenges team
6 March 2024 -- London, UK -- A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle...
Category: Clinical Trials, Pharmaceutical
Posted: March 6, 2024
Global Clinical Trial Supply Leader partners with Pill Connect to deliver greater confidence in clinical trial outcomes
5 March 2024 -- Manchester, UK -- Pill Connect, the smart dosing device company, today announces its acceptance onto the leading CDMO’s (Contract development and manufacturing organisation) smart packaging supply...
Category: Clinical Trials, Drug Delivery, Logistics
Posted: March 5, 2024
Exonate first-in-class eye drop phase 1b/2a trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications Data generated fully supports continued clinical development of EXN407...
Category: Clinical Trials
Posted: March 5, 2024
New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood
Blood-based diagnostic effectively discriminated between patients who were positive versus negative for amyloid beta on PET scans Data will be shared in a poster presentation at AD/PD 2024 on 8-9...
Category: Biotechnology
Posted: March 5, 2024
Audion Therapeutics and the REGAIN Consortium Announce Publication in Nature Communications of Their Phase 1/2a Trial of an Intratympanic Gamma Secretase Inhibitor for the Treatment of Mild to Moderate Sensorineural Hearing Loss
The phase 1 part of the study (Multiple Ascending Dose of 3 administrations) confirms safety and tolerability of a dose of 250 microgram of Gamma Secretase Inhibitor LY3056480 Pre-defined Primary...
Category: Clinical Trials
Posted: March 4, 2024
Linnaeusparkweg 10-2, 1098 EA Amsterdam, Netherlands
SolasCure Publishes Phase 2a Clinical Trial Report in Leading Wound Care Journal
Publication in the ‘International Wound Journal’ provides robust validation of the phase 2a trial data that will enable further clinical studies Study demonstrates proof-of-concept and strong safety profile of Aurase...
Category: Biotechnology
Posted: March 4, 2024
WCG Expands New Statistical Consulting Solutions to Address Industry Resource Challenges
4 March 2024 -- New Jersey, US -- WCG, the global leader in providing solutions that measurably improve and accelerate clinical research, announces the expansion of its capabilities with the...
Category: Clinical Trials
Posted: March 4, 2024
PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases
New collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions 29 February 2024 -- Manchester, UK -- PharmaKure, a clinical stage...
Category: Other
Posted: February 29, 2024
Alderley Park Congleton Road Nether Alderley Open Access Lab 19S6 Macclesfield SK10 4TG
Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD 2024 Conference
Galimedix’s novel, orally administered small molecule offers the hope of changing the course of disease by targeting amyloid beta oligomers and protofibrils 28 February 2024 -- Maryland, US -- Galimedix...
Category: Biotechnology
Posted: February 28, 2024
Aotearoa Clinical Trials Becomes First Site in New Zealand to Achieve both GCSA Certification and Silver Workforce Quality Accreditation
Certifications demonstrate Aotearoa Clinical Trials is working to the highest global best-practice standards, ratified by the industry 21 February 2024 -- Auckland, New Zealand and Maidenhead, UK -- Aotearoa Clinical Trials...
Category: Clinical Trials
Posted: February 21, 2024
Esme Green Building Middlemore Hospital 100 Hospital Rd Papatoetoe, 2025 Auckland, New Zealand
Principal IRB Becomes Univo IRB With Support From QHP Capital
20 February 2024 -- North Carolina -- Today, Univo IRB was announced as the new company name for Principal IRB. Univo IRB is a next generation institutional review board (IRB) recently acquired...
Category: Clinical Trials
Posted: February 20, 2024
First MYC inhibitor to demonstrate safety and anti-tumour activity in a phase 1 first-in-human clinical trial
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in most, if not all tumor types. Until recently, MYC has...
Category: Drug Discovery
Posted: February 7, 2024
